Skip to main content

Table 5 Univariate and multivariate Cox proportional hazards model for overall survival and progression-free survival

From: Prognostic significance of lung radiation dose in patients with esophageal cancer treated with neoadjuvant chemoradiotherapy

Characteristics OS PFS
Univariate Multivariate Univariate Multivariate
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Age 0.97 (0.94–1.00) 0.08 0.97 (0.93–1.00) 0.08 0.96 (0.93–1.00) 0.03 0.97 (0.93–1.00) 0.07
BMI 0.99 (0.91–1.07) 0.74    1.05 (0.97–1.13) 0.22   
ECOG PS (1 vs. 0) 1.56 (0.83–2.91) 0.17    1.39 (0.74–2.61) 0.30   
Clinical T (T3–4 vs. T1–2) 1.06 (0.62–1.80) 0.84    0.93 (0.54–1.58) 0.78   
Clinical N (N+ vs. N0) 1.16 (0.50–2.70) 0.72    1.79 (0.72–4.46) 0.21   
cTNM stage (III vs. II) 0.89 (0.50–1.56) 0.67    0.68 (0.40–1.17) 0.16   
Time from NCRT to surgery 1.01 (0.94–1.09) 0.72    0.98 (0.91–1.06) 0.59   
Surgical margin (R1 vs. R0) 2.62 (1.41–4.85) 0.002 3.63 (1.59–8.28) 0.002 4.37 (2.46–7.77) < 0.001 4.16 (2.11–8.19) < 0.001
TRG (2/3 vs. 0/1) 3.42 (2.00–5.84) < 0.001 2.84 (1.50–5.37) 0.001 2.39 (1.44–3.98) 0.001 2.31 (1.30–4.12) 0.004
Gross tumor volume 1.003 (1.000–1.005) 0.09 0.998 (0.994–1.002) 0.27 1.001 (0.998–1.004) 0.44   
Target volume 1.00 (1.00–1.00) 0.12    1.00 (1.00–1.00) 0.63   
Radiation dose 1.00 (1.00–1.00) 0.16    1.00 (1.00–1.00) 0.32   
DVH of lunga
 V5 1.02 (1.01–1.03) 0.001 1.02 (1.00–1.05) 0.03 1.01 (1.00–1.02) 0.03 1.01 (0.99–1.03) 0.21
 V20 1.07 (1.04–1.11) < 0.001 1.09 (1.04–1.14) < 0.001 1.06 (1.02–1.10) 0.002 1.07 (1.03–1.12) 0.001
 Mean heart dose 1.00 (1.00–1.01) 0.03 1.00 (1.00–1.00) 0.55 1.00 (1.00–1.00) 0.41   
  1. Abbreviations: BMI body mass index, CI confidence interval, DVH dose-volume histogram, ECOG Eastern Cooperative Oncology Group, HR hazard ratio, NCRT neoadjuvant chemo-radiotherapy, TRG tumor regression grade, PS performance status
  2. Bolded p-values are those significant with a p < 0.05
  3. aVx = volume (mL) of lung receiving X Gy or more